Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AMP013
MIFTS: 40

Ampulla of Vater Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ampulla of Vater Cancer

About this section

MalaCards integrated aliases for Ampulla of Vater Cancer:

Name: Ampulla of Vater Cancer 12 12 15
Ampulla of Vater Carcinoma 12 15 17
Ampullary Carcinoma 12 58
Malignant Tumour of Ampulla of Vater 12
Carcinoma of the Ampulla of Vater 58
Carcinoma of Ampulla of Vater 12
Ampulloma 58

Characteristics:

Orphanet epidemiological data:

58
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:10020 DOID:4932
ICD9CM 34 156.2
NCIt 50 C3536 C3908
SNOMED-CT 67 254609000 93668007
ICD10 32 C24.1
ICD10 via Orphanet 33 C24.1
UMLS via Orphanet 72 C0262401
Orphanet 58 ORPHA300557
UMLS 71 C0153454 C0262401
Sources

Summaries for Ampulla of Vater Cancer

About this section
MalaCards based summary : Ampulla of Vater Cancer, also known as ampulla of vater carcinoma, is related to acute cholangitis and ampulla of vater neoplasm. An important gene associated with Ampulla of Vater Cancer is MIR196A1 (MicroRNA 196a-1), and among its related pathways/superpathways are Gastric cancer and VEGF Signaling. The drugs Oxaliplatin and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and breast, and related phenotype is digestive/alimentary.

Sources

Related Diseases for Ampulla of Vater Cancer

About this section

Diseases related to Ampulla of Vater Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 acute cholangitis 30.7 MUC5AC MUC1 CEACAM5
2 ampulla of vater neoplasm 30.6 KRAS HRAS
3 ampulla of vater adenocarcinoma 30.6 MUC5AC MUC1 MIRLET7G MIR377 MIR30D MIR196A1
4 small cell carcinoma 30.4 TP53 MUC1 KRT7 KRT20 KRAS CDX2
5 sarcomatoid carcinoma 30.4 MUC1 KRT7 KRT20 KRAS
6 acinar cell carcinoma 30.3 TP53 SMAD4 KRT7
7 in situ carcinoma 30.2 TP53 MUC1 KRT17 HRAS
8 cholecystitis 30.1 TP53 MUC6 MUC5AC MUC1
9 neuroendocrine carcinoma 30.1 MUC1 KRT7 KRT20 CEACAM5
10 klatskin's tumor 30.0 TP53 KRT7 CEACAM5
11 squamous cell carcinoma 29.9 TP53 SMAD4 MUC1 KRT7 HRAS CEACAM5
12 familial adenomatous polyposis 29.9 TP53 SMAD4 KRAS HRAS
13 papillary adenocarcinoma 29.9 TP53 MUC1 KRT7 CEACAM5
14 microinvasive gastric cancer 29.8 TP53 MUC6 MUC5AC MIR196A1 CEACAM5 CDX2
15 pancreatic adenocarcinoma 29.8 TP53 SMAD4 KRAS HRAS
16 large cell carcinoma 29.7 MUC1 KRT7 KRT20 KRAS HRAS CEACAM5
17 pancreatic ductal adenocarcinoma 29.7 TP53 SMAD4 MUC1 MIR196A1 MIR145 KRAS
18 adenosquamous carcinoma 29.6 TP53 SMAD4 MUC1 KRT7 KRAS CEACAM5
19 papilloma 29.6 TP53 KRT7 KRT20 KRAS
20 tubular adenocarcinoma 29.3 MUC5AC MUC1 KRT7 KRT20 CEACAM5 CDX2
21 gallbladder cancer 29.3 TP53 MUC1 MIR145 KRAS CEACAM5
22 adenocarcinoma 29.2 TP53 SMAD4 MUC1 KRT7 KRAS HRAS
23 intrahepatic cholangiocarcinoma 29.1 TP53 SMAD4 MUC5AC MUC1 KRT7 KRT20
24 gastric adenocarcinoma 29.1 TP53 SMAD4 KRT20 KRAS HRAS CEACAM5
25 pancreatic ductal carcinoma 28.9 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
26 adenoma 28.8 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
27 cholangiocarcinoma 28.7 TP53 SMAD4 MUC5AC MUC1 KRT7 KRT20
28 duodenum cancer 28.1 TP53 SMAD4 MUC6 MUC5AC MUC1 MIR196A1
29 bile duct cancer 28.1 TP53 SMAD4 MUC6 MUC5AC MUC1 MIR145
30 signet ring cell adenocarcinoma 28.1 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
31 pancreatic cancer 27.7 TP53 SMAD4 MUC6 MUC5AC MUC1 MIR196A1
32 ampulla of vater squamous cell carcinoma 11.3
33 ampulla of vater adenosquamous carcinoma 11.3
34 large cell neuroendocrine carcinoma 10.7
35 acute pancreatitis 10.5
36 papillary carcinoma 10.4
37 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
38 scrotum paget's disease 10.4 MUC1 KRT7
39 anal canal paget's disease 10.4 KRT7 CDX2
40 gastric signet ring cell adenocarcinoma 10.4 KRT7 CDX2
41 gallbladder signet ring cell adenocarcinoma 10.4 MUC1 KRT7
42 adenosquamous colon carcinoma 10.4 KRT7 CDX2
43 bartholin's gland disease 10.4 KRT7 CDX2
44 bartholin's gland carcinoma 10.4 KRT7 CDX2
45 colloid carcinoma of the pancreas 10.4 MUC5AC MUC1
46 rectum neuroendocrine neoplasm 10.4 KRT7 CDX2
47 middle ear adenoma 10.4 MUC1 KRT7
48 ethmoid sinus cancer 10.4 HRAS CDX2
49 bladder benign neoplasm 10.4 KRT7 KRT20
50 hepatic flexure cancer 10.3 KRAS HRAS

Graphical network of the top 20 diseases related to Ampulla of Vater Cancer:



Diseases related to Ampulla of Vater Cancer
Sources

Symptoms & Phenotypes for Ampulla of Vater Cancer

About this section

MGI Mouse Phenotypes related to Ampulla of Vater Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.23 CDX2 ELF3 HRAS KRAS KRT17 MUC5AC
Sources

Drugs & Therapeutics for Ampulla of Vater Cancer

About this section

Drugs for Ampulla of Vater Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
2
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
3
Gemcitabine Approved Phase 2 95058-81-4 60750
4
leucovorin Approved Phase 2 58-05-9 6006
5
Fluorouracil Approved Phase 2 51-21-8 3385
6
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
7
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
9 Micronutrients Phase 2
10 Nutrients Phase 2
11 Vitamin B Complex Phase 2
12 Immunosuppressive Agents Phase 2
13 Liver Extracts Phase 2
14 Trace Elements Phase 2
15 Protective Agents Phase 2
16 Vitamins Phase 2
17 Anti-Infective Agents Phase 2
18 Antimetabolites Phase 2
19 Hormones Phase 2
20 Antiviral Agents Phase 2
21 Vitamin B9 Phase 2
22 Calcium, Dietary Phase 2
23 Folate Phase 2
24 Immunologic Factors Phase 2
25 Antidotes Phase 2
26 Folic Acid Antagonists Phase 1, Phase 2
27 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
28
Calcium Nutraceutical Phase 2 7440-70-2 271
29
Iodine Approved, Investigational 7553-56-2 807
30
Cadexomer iodine Experimental 94820-09-4
31 Cola

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
2 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
3 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
4 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
5 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes Recruiting NCT04171700 Phase 2 Rucaparib
6 Intraluminal Implantation of Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613
7 Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial Completed NCT01844245
8 Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma Recruiting NCT03800212 treatment for ampullary adenocarcinoma
9 A Prospective Case Control Study on the Prevalence of Small Bowel and Colonic Polyps in Patients With Duodenal Adenomas/Ampullomas Who do Not Have Familial Adenomatous Polyposis (FAP) or Peutz Jeghers Syndrom (PJS). Active, not recruiting NCT02470416

Search NIH Clinical Center for Ampulla of Vater Cancer

Sources

Genetic Tests for Ampulla of Vater Cancer

About this section
Sources

Anatomical Context for Ampulla of Vater Cancer

About this section

MalaCards organs/tissues related to Ampulla of Vater Cancer:

40
Liver, Lymph Node, Breast, Neutrophil
Sources

Publications for Ampulla of Vater Cancer

About this section

Articles related to Ampulla of Vater Cancer:

(show top 50) (show all 120)
# Title Authors PMID Year
1
Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. 61
33541011 2021
2
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. 61
33592563 2021
3
Adverse oncologic effects of preoperative biliary drainage on early stage ampulla of Vater cancer. 61
32665175 2021
4
Prognostic importance of numbers of retrieved lymph nodes and positive lymph nodes for ampulla of vater cancer (AVC) in 2347 patients from the Surveillance, Epidemiology, and End Results (SEER) database. 61
33449948 2021
5
Recent advances of immunotherapy for biliary tract cancer. 61
33215952 2021
6
The Prognostic Relevance of the Number and Location of Positive Lymph Nodes for Ampulla of Vater Carcinoma. 61
32909124 2021
7
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. 61
33307876 2020
8
Nivolumab: an investigational agent for the treatment of biliary tract cancer. 61
33307866 2020
9
Role of cholangitis in predicting survival in patients with carcinoma of the ampulla of vater. 61
32823087 2020
10
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. 61
33171024 2020
11
Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. 61
32652820 2020
12
Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. 61
32437829 2020
13
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. 61
33054456 2020
14
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. 61
32781527 2020
15
A Comparative Study of Laparoscopic versus Open Pancreaticoduodenectomy for Ampulla of Vater Carcinoma. 61
32668683 2020
16
Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. 61
31214805 2020
17
Preoperative prognostic nutritional index as an independent prognostic factor for resected ampulla of Vater cancer. 61
32126069 2020
18
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. 61
33356500 2020
19
Influence of bile contamination for patients who undergo pancreaticoduodenectomy after biliary drainage. 61
31885425 2019
20
Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. 61
31127946 2019
21
ASO Author Reflections: The Accurate Prognostic Evaluation and Optimal Treatment Strategy for Ampulla of Vater Carcinoma. 61
31115854 2019
22
[Prediction model for survival in patients with biliary tract cancer: a development and validation study]. 61
31838822 2019
23
Role of systemic inflammation in predicting the prognosis of ampulla of Vater carcinoma. 61
31196491 2019
24
The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma. 61
30790111 2019
25
Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 61
30753687 2019
26
Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. 61
30645774 2019
27
Incidence and Mortality Rates of Second Pancreatic Cancer Among Survivors of Digestive Cancers: A Nationwide Population-Based Study. 61
30768577 2019
28
Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology. 61
30625267 2019
29
Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. 61
30155920 2019
30
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. 61
30451797 2019
31
Ampulla of Vater carcinoma: Molecular landscape and clinical implications. 61
30487949 2018
32
Sarcomatoid Adenocarcinoma of the Ampulla of Vater. 61
29887717 2018
33
Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. 61
29452703 2018
34
The prognostic impact of differentiation at the invasive front of biliary tract cancer. 61
29572828 2018
35
Ampullary carcinoma-A genetic perspective. 61
29807574 2018
36
Impact of preoperative endoscopic cholangiography and biliary drainage in Ampulla of Vater cancer. 61
29549909 2018
37
Survival rates are higher in married patients with biliary tract cancer: a population-based study. 61
29507708 2018
38
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. 61
27611608 2018
39
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. 61
28502094 2017
40
Impact of delayed gastric emptying after pancreaticoduodenectomy on survival. 61
28547910 2017
41
Proposed new staging system for ampulla of Vater cancer with greater discriminatory ability: multinational study from eastern and western centers. 61
28660632 2017
42
Genetic alterations in Japanese extrahepatic biliary tract cancer. 61
28693246 2017
43
Bilateral lung metastasectomy in carcinoma of the ampulla of Vater. 61
28168842 2017
44
Metastasectomy for recurrent or metastatic biliary tract cancers: A single center experience. 61
29199665 2017
45
Diet and biliary tract cancer risk in Shanghai, China. 61
28288186 2017
46
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. 61
27780932 2016
47
KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. 61
27517148 2016
48
Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. 61
27267833 2016
49
The clinical characteristics and manifestations of cytomegalovirus esophagitis. 61
25715747 2016
50
Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. 61
26546182 2016
Sources

Variations for Ampulla of Vater Cancer

About this section
Sources

Expression for Ampulla of Vater Cancer

About this section
Search GEO for disease gene expression data for Ampulla of Vater Cancer.
Sources

Pathways for Ampulla of Vater Cancer

About this section

Pathways related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Gastric cancer 36
Show member pathways
 12.52 TP53 SMAD4 KRAS HRAS CDX2
2
VEGF Signaling 66
Show member pathways
 12.18 TP53 SMAD4 MUC1 KRAS HRAS
3
Human T-cell leukemia virus 1 infection 36
12.05 TP53 SMAD4 KRAS HRAS
4
CLEC7A (Dectin-1) signaling 65
Show member pathways
 11.77 MUC6 MUC5AC MUC1 KRAS HRAS
5
MicroRNAs in cancer 36
11.59 TP53 MIRLET7G MIR30D MIR145 KRAS HRAS
6
Bladder cancer 36 1
11.52 TP53 KRAS HRAS
7
DNA Damage Response (only ATM dependent) 1
11.52 TP53 SMAD4 KRAS HRAS
8
Central carbon metabolism in cancer 36
11.45 TP53 KRAS HRAS
9
Mitophagy - animal 36
11.38 TP53 KRAS HRAS
10
Extracellular vesicle-mediated signaling in recipient cells 1
10.91 SMAD4 KRAS HRAS
11
p38MAPK events 65
10.61 KRAS HRAS
Sources

GO Terms for Ampulla of Vater Cancer

About this section

Biological processes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.54 TP53 KRAS HRAS
2 gene silencing by miRNA GO:0035195 9.43 MIRLET7G MIR377 MIR30D MIR196A1 MIR187 MIR145
3 O-glycan processing GO:0016266 9.33 MUC6 MUC5AC MUC1
4 response to isolation stress GO:0035900 9.32 KRAS HRAS
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 MUC1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 MUC6 MUC5AC MUC1 KRAS HRAS
Sources

Sources for Ampulla of Vater Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....